PIII
P3 Health Partners Inc. NASDAQ Listed Apr 6, 2021$10.80
After hrs
$10.70
-0.93%
Mkt Cap $35.4M
52w Low $1.52
60.4% of range
52w High $16.89
50d MA $8.45
200d MA $5.85
P/E (TTM)
—
EV/EBITDA
—
P/B
—
Debt/Equity
-1.9x
ROE
95.3%
P/FCF
-0.4x
RSI (14)
48.00
ATR (14)
$1.24
Beta
0.56
50d MA
$8.45
200d MA
$5.85
Avg Volume
2.6M
P3 Health Partners Inc., a patient-centered and physician-led population health management company, provides superior care services in the United States. It operates clinics and wellness centers. The company is based in Henderson, Nevada.
2370 Corporate Circle · Henderson, NV 89074 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 26, 2026 | AMC | -8.06 | -23.02 | -185.5% | 2.79 | -2.2% | +5.4% | +0.7% | +4.1% | -11.0% | -6.2% | — |
| Nov 14, 2025 | AMC | -5.29 | -9.67 | -82.7% | 6.84 | +0.0% | -12.6% | +7.0% | -4.4% | -4.1% | -2.7% | — |
| Aug 14, 2025 | AMC | -3.29 | -6.23 | -89.4% | 6.94 | +0.0% | -2.3% | +2.5% | +3.2% | +2.1% | -0.1% | — |
| May 15, 2025 | AMC | -5.00 | -6.28 | -25.6% | 8.30 | -1.2% | -3.7% | -0.6% | +1.3% | -2.9% | -2.6% | — |
| Mar 27, 2025 | AMC | -8.50 | -16.00 | -88.2% | 9.05 | -0.6% | -4.4% | -5.2% | +12.2% | -0.5% | -4.9% | — |
| Nov 12, 2024 | AMC | -1.50 | -15.50 | -933.3% | 19.50 | -20.5% | -35.9% | -16.4% | +9.6% | -7.4% | -0.5% | — |
| Aug 7, 2024 | AMC | -4.00 | -7.50 | -87.5% | 30.80 | -2.6% | -4.1% | +2.7% | -8.9% | +9.0% | -2.2% | — |
| May 8, 2024 | AMC | -9.50 | -8.00 | +15.8% | 37.30 | -1.3% | -1.9% | -8.2% | -6.2% | +6.3% | -8.4% | — |
| Mar 28, 2024 | AMC | -9.50 | -11.00 | -15.8% | 51.50 | -1.0% | -14.1% | -10.5% | -0.3% | +3.7% | -1.5% | — |
| Nov 8, 2023 | AMC | -11.50 | -6.00 | +47.8% | 65.50 | +6.1% | +6.1% | -2.9% | -4.1% | -6.6% | +8.3% | — |
| Aug 7, 2023 | AMC | -12.00 | -4.50 | +62.5% | 107.00 | +26.2% | +4.7% | -2.2% | +1.4% | -10.8% | -6.6% | — |
| May 10, 2023 | AMC | -4.50 | -11.00 | -144.4% | 111.00 | -3.2% | +4.1% | +13.9% | +15.2% | +5.9% | +5.6% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 2 | TD Cowen | Maintains | Hold → Hold | — | $2.74 | $2.67 | -2.6% | -6.2% | -1.9% | +0.8% | +8.3% | -4.0% |
| Mar 27 | Lake Street | Maintains | Buy → Buy | — | $2.79 | $2.73 | -2.2% | +5.4% | +0.7% | +4.1% | -11.0% | -6.2% |
| Nov 17 | Lake Street | Maintains | Buy → Buy | — | $6.84 | $6.84 | +0.0% | -12.6% | +7.0% | -4.4% | -4.1% | -2.7% |
| Apr 21 | Lake Street | Maintains | Buy → Buy | — | $9.24 | $9.08 | -1.7% | -6.2% | +2.5% | +0.0% | +6.9% | -5.9% |
| Nov 20 | TD Cowen | Maintains | Hold → Hold | — | $10.55 | $10.50 | -0.5% | -3.3% | +5.4% | -0.9% | +0.0% | +10.8% |
| Apr 1 | BTIG | Downgrade | Buy → Neutral | — | $51.50 | $51.00 | -1.0% | -14.1% | -10.5% | -0.3% | +3.7% | -1.5% |
| Mar 14 | Lake Street | Maintains | Buy → Buy | — | $40.50 | $38.50 | -4.9% | -12.7% | +44.3% | -5.2% | +1.3% | -5.6% |
| Jan 4 | William Blair | Maintains | Outperform → Outperform | — | $324.50 | $330.00 | +1.7% | -3.7% | -8.5% | -4.7% | -8.1% | +3.8% |
No insider trades available.
8-K
P3 Health Partners Inc. -- 8-K Filing
P3 Health Partners approved issuance of 3.3 million Class A shares upon VBC Growth SPV 5's warrant exercise, potentially diluting existing shareholders' ownership stakes.
Jun 10
8-K
P3 Health Partners Inc. -- 8-K Filing
May 26
8-K · 2.02
!! High
P3 Health Partners Inc. -- 8-K 2.02: Earnings Results
P3 Health Partners announced earnings results, with the full press release available as an exhibit in this 8-K filing for investor review and financial analysis.
May 14
8-K
Unknown — 8-K Filing
P3's improved contract economics and operational discipline suggest margin expansion potential ahead, making the 2026 guidance critical to whether management can execute this turnaround amid competitive population health pressures.
Mar 26
8-K · 1.01
!! High
Unknown — 8-K 1.01: Material Agreement
PIII faces revenue risk if it fails 2026 performance metrics or loses key personnel, potentially losing a material client relationship and facing transition obligations that could strain resources.
Mar 25
8-K · 5.02
!!! Very High
Unknown — 8-K 5.02: Executive Change
An executive change at PIII requires careful review of the full agreement exhibits to assess leadership continuity impact and potential implications for company strategy and shareholder value.
Mar 18
8-K · 1.01
! Medium
P3 Health Partners Inc. -- 8-K 1.01: Financing / Debt Agreement
P3 Health Partners secured a $19.0 million financing agreement with VBC Growth SPV 5, LLC, providing capital to support operations and growth initiatives.
Feb 17
Institutional (13F) — Top 10
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Vanguard Capital Management Llc | 70,627 | $218K | New | Mar 2026 |
| 2 | Diversified Trust Co | 20,316 | $63K | New | Mar 2026 |
| 3 | Nine Masts Capital Ltd | 17,964 | $55K | New | Mar 2026 |
| 4 | Hrt Financial Lp | 15,092 | $46K | New | Mar 2026 |
| 5 | Susquehanna International Group, Llp | 13,371 | $41K | New | Mar 2026 |
| 6 | Blair William & Co/il | 3,092 | $10K | — | Mar 2026 |
| 7 | Ubs Group Ag | 1,840 | $6K | Added | Mar 2026 |
| 8 | Bnp Paribas Financial Markets | 36 | $111 | — | Mar 2026 |
| 9 | Jpmorgan Chase & Co | 19 | $56 | — | Mar 2026 |
| 10 | Royal Bank Of Canada | 2 | — | — | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 8
All ↗
| # | Fund | Shares | Value | Period |
|---|---|---|---|---|
| 1 | Fidelity Extended Market Index Fund | 9,357 | $20K | Feb 2026 |
| 2 | iShares Micro-Cap ETF | 3,051 | $9K | Mar 2026 |
| 3 | Fidelity Total Market Index Fund | 3,210 | $7K | Feb 2026 |
| 4 | Fidelity Nasdaq Composite Index ETF | 3,078 | $6K | Feb 2026 |
| 5 | Fidelity Series Total Market Index Fund | 2,437 | $5K | Feb 2026 |
| 6 | Dimensional U.S. Core Equity 2 ETF | 1,632 | $3K | Jan 2026 |
| 7 | Fidelity Nasdaq Composite Index Fund | 610 | $1K | Feb 2026 |
| 8 | Knights of Columbus U.S. ALL CAP INDEX FUND | 7 | $14 | Jan 2026 |
Valuation
Market Cap
$35.4M
Enterprise Value
$242.4M
P/E (TTM)
—
Forward P/E
—
PEG Ratio
0.02x
P/B
—
P/S
0.02x
P/FCF
-0.43x
EV/EBITDA
—
Shares Out
3.3M
Financials (TTM)
Revenue
$1.47B
Net Income
-$126.2M
EBITDA
-$138.6M
Free Cash Flow
-$91.2M
Op Cash Flow
-$91.2M
EPS Basic
$-45.26
EPS Diluted
$-38.60
EPS Forward
$-9.44
Gross Margin
50.6%
Op Margin
-15.2%
Net Margin
-8.6%
Balance Sheet
Total Assets
$656.6M
Total Liab.
$796.9M
Total Equity
-$140.2M
Cash
$25.0M
LT Debt
$228.4M
Book Value/Sh
$-42.90
Debt/Equity
-1.85x
Current Ratio
0.24
Quick Ratio
0.24
Returns & Growth
ROE
95.3%
ROA
-22.5%
ROIC
-170.2%
Rev Growth YoY
-2.8%
EPS Growth YoY
+3.3%
Price Returns
2W
-2.4%
1M
-2.0%
3M
+303.4%
6M
+237.3%
12M
+89.5%
Technicals
52W High
$16.89
52W Low
$1.52
50d MA
$8.45
200d MA
$5.85
RSI (14)
48.00
ATR (14)
$1.24
Beta
0.56
Avg Volume
2.6M
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$4.00
High
$4.00
Low
$4.00
Median
$4.00
Data updated apr 26, 2026 7:41pm
· Source: financialmodelingprep.com